[1]苗培田.靶向药物赫赛汀治疗转移性乳腺癌的研究[J].医学信息,2019,32(09):45-47.[doi:10.3969/j.issn.1006-1959.2019.09.015]
　MIAO Pei-tian.Targeted Drug Herceptin in the Treatment of Metastatic Breast Cancer[J].Journal of Medical Information,2019,32(09):45-47.[doi:10.3969/j.issn.1006-1959.2019.09.015]
点击复制

靶向药物赫赛汀治疗转移性乳腺癌的研究()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
32卷
期数:
2019年09期
页码:
45-47
栏目:
综述
出版日期:
2019-05-01

文章信息/Info

Title:
Targeted Drug Herceptin in the Treatment of Metastatic Breast Cancer
文章编号:
1006-1959（2019）09-0045-03
作者:
苗培田
（天津市宁河区医院肿瘤科，天津 301500）
Author(s):
MIAO Pei-tian
(Department of Oncology,Ninghe District Hospital,Tianjin 301500,China)
关键词:
转移性乳腺癌; 赫赛汀; 靶向药物
Keywords:
Metastatic breast cancer; Herceptin; Targeted drugs
分类号:
R737.9
DOI:
10.3969/j.issn.1006-1959.2019.09.015
文献标志码:
A
摘要:
乳腺癌为女性常见恶性肿瘤之一，为女性常见癌症第2大死因。乳腺虽不属于人体不可或缺的器官，且原位癌也不致命，随着病情进展速度逐渐加快，癌细胞后期发展至脱落会转移，侵犯至患者心、脑等重要脏器器官，危害患者生命健康。现阶段对乳腺癌相关治疗措施包括手术、放疗、化疗及内分泌治疗等。赫赛汀以癌细胞作为靶点，能进一步抑制转移性乳腺癌发展，本文就近年来所报道的文献结合我院实际开展情况进行以下总结，为后续临床工作者提供理论参考。
Abstract:
Breast cancer is one of the common malignant tumors in women, and it is the second leading cause of cancer in women. Although the breast is not an indispensable organ of the human body, and the cancer in situ is not fatal, as the disease progresses, the speed of the cancer gradually increases, and the cancer cells will metastasize and metastasize to metastasize, invading the vital organs of the heart and brain of the patient, and harming the patient. Life is healthy. Current treatments for breast cancer include surgery, radiotherapy, chemotherapy and endocrine therapy. Herceptin can further inhibit the development of metastatic breast cancer by using cancer cells as a target. This paper summarizes the literature reported in recent years and combines the actual development of our hospital to provide a theoretical reference for follow-up clinicians.

参考文献/References:

[1]刘丹,杨争艳,王涛,等.肾上腺素能信号在乳腺癌赫赛汀耐药中的意义及其机制研究[J].中国病理生理杂志,2015,31(10):1839-1840.
[2]Seo MJ,Lee JJ,Kim HO,et al.Detection of internal mammary lymph node metastasis with 18F-fluorodeoxyglucose positron emission tomography/computed tomography in patients with stageⅢ breast cancer[J].European Journal of Nuclear Medicine and Molecular Imaging,2014,41(3):438-445.
[3]黄永惠.Ⅱ/Ⅲ期乳腺癌采用CEF方案联合赫赛汀靶向治疗的临床研究[J].中国妇幼保健,2018,33(16):3824-3826.
[4]张欲晓,殷潇,田梦媛,等.赫赛汀治疗HER-2阳性乳腺癌的医保预算影响分析[J].中国卫生经济,2016,35(12):63-66.
[5]邓婷婷,陈彬,王继红,等.HER2变异体在乳腺癌进程和赫赛汀抵抗中的临床意义[J].现代肿瘤医学,2015,23(6):859-861.
[6]袁超,郭书坤,杨其峰,等.长链非编码RNA H19对人乳腺癌细胞BT-474赫赛汀抵抗影响机制探讨[J].中华肿瘤防治杂志,2017,24(24):1712-1717.
[7]郑晓青,李浩.赫赛汀对人乳腺癌细胞侵袭转移能力的影响[J].中国临床药理学与治疗学,2015,20(7):759-762,768.
[8]闻国权,吴淑仪,黎冠宏,等.赫赛汀联合阿霉素脂质体治疗HER-2阳性乳腺癌的肿瘤负荷及毒副反应评估[J].海南医学院学报,2016,22(23):2869-2872.
[9]洪慧,姚满红,李玉凤,等.赫赛汀联合紫杉醇序贯 FEC 新辅助治疗晚期乳腺癌1例[J].中国煤炭工业医学杂志,2016,19(4):566-568.
[10]Zhang J,Dewilde AH,Chinn P,et al.Herceptin-directed nanoparticles activated by an alternating magnetic field selectively kill HER-2 positive human breast cells in vitro via hyperthermia[J].International journal of hyperthermia:The official journal of European Society for Hyperthermic Oncology,North American Hyperthermia Group,2011,27(7):682-697.
[11]卢晓婷,齐杰.赫赛汀治疗乳腺癌的心脏毒性反应及其影响因素[J].中国药物与临床,2016,16(10):1463-1466.
[12]Riches A,Campbell E,Borger E,et al.Regulation of exosome release from mammary epithelial and breast cancer cells-A new regulatory pathway[J].European Journal of Cancer,2014,50(5):1025-1034.
[13]Cleary AS,Leonard TL,Gestl SA,et al.Tumour cell heterogeneity maintained by cooperating subclones in Wnt-driven mammary cancers[J].Nature,2014,508(7494):113-117.
[14]何敏,邓丽聪.赫赛汀联合紫杉醇新辅助化疗对HER-2阳性乳腺癌细胞增殖活力的影响[J].海南医学院学报,2018,24(17):1603-1606.
[15]李蕾帆,汪秀云,许辉琼,等.赫赛汀联合紫杉醇+替吉奥二线方案对Her-2阳性胃癌患者恶性程度及血管新生的影响[J].海南医学院学报,2016,22(23):2837-2840.
[16]石峰.曲妥珠单抗联合紫杉醇卡铂方案新辅助化疗治疗H ER-2阳性乳腺癌疗效及不良反应分析[J].医学理论与实践,2016,29(17):3017-3019.
[17]伍亚伟,胡建铭,石怡珍,等.多西紫杉醇对人卵巢癌SKOV3裸鼠移植瘤的抑制作用及其与顺铂、曲妥珠单抗联合作用的探讨[J].国际妇产科学杂志,2017,44(1):48-51.
[18]杨思福,黄建瑾.吉西他滨联合长春瑞滨治疗耐药性晚期乳腺癌疗效观察[J].实用肿瘤杂志,2015,30(5):462-464.
[19]Ewaschuk JB,Newell M,Field CJ,et al.Docosahexanoic acid improves chemotherapy efficacy by inducing CD95 translocation to lipid rafts in ER 2 breast cancer cells[J].Lipids,2012,47(11): 1019-1030.
[20]刘玉琳,夏宇,刘婧,等.乳腺癌患者凝血指标与赫赛汀治疗效应的相关性分析[J].国际检验医学杂志,2016,37(17):2384-2386.

相似文献/References:

[1]张晓玲.替吉奥联合多西他赛治疗转移性乳腺癌的临床疗效观察[J].医学信息,2018,31(20):128.[doi:10.3969/j.issn.1006-1959.2018.20.038]
　ZHANG Xiao-ling.Clinical Observation of Tegafur,Gimeracil and Oteracil Porassium Capsules Combined with Docetaxel in the Treatment of Metastatic Breast Cancer[J].Journal of Medical Information,2018,31(09):128.[doi:10.3969/j.issn.1006-1959.2018.20.038]
[2]曹越越,潘跃银.吉西他滨治疗HER-2阴性转移性乳腺癌疗效的影响因素[J].医学信息,2021,34(14):70.[doi:10.3969/j.issn.1006-1959.2021.14.020]
　CAO Yue-yue,PAN Yue-yin.Factors Influencing the Efficacy of Gemcitabine in the Treatment of HER-2 Negative Metastatic Breast Cancer[J].Journal of Medical Information,2021,34(09):70.[doi:10.3969/j.issn.1006-1959.2021.14.020]

更新日期/Last Update: 2019-05-01